{"id":1838,"date":"2023-03-03T11:48:40","date_gmt":"2023-03-03T11:48:40","guid":{"rendered":"http:\/\/proboostnow.eu\/?page_id=1838"},"modified":"2024-09-18T12:26:22","modified_gmt":"2024-09-18T12:26:22","slug":"co-je-thymic-protein-a","status":"publish","type":"page","link":"https:\/\/proboostnow.eu\/en_us\/co-je-thymic-protein-a\/","title":{"rendered":"CO JE THYMIC PROTEIN A"},"content":{"rendered":"<div class=\"banner has-hover bg-zoom-fade\" id=\"banner-1033273354\">\n          <div class=\"banner-inner fill\">\n        <div class=\"banner-bg fill\" >\n            <img loading=\"lazy\" decoding=\"async\" width=\"1020\" height=\"681\" src=\"https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/02\/pexels-pavel-danilyuk-8442533-scaled-e1677844277339-1024x684.jpg\" class=\"bg attachment-large size-large\" alt=\"co je tpa\" \/>                                    \n                    <\/div>\n\t\t\n        <div class=\"banner-layers container\">\n            <div class=\"fill banner-link\"><\/div>            \n\n   <div id=\"text-box-414654082\" class=\"text-box banner-layer x50 md-x50 lg-x50 y50 md-y50 lg-y50 res-text\">\n                                <div class=\"text-box-content text dark\">\n              \n              <div class=\"text-inner text-center\">\n                  \n\n\t<div id=\"text-2445156186\" class=\"text\">\n\t\t\n\n<h2>Co je Thymic Protein A<\/h2>\n<h5>z\u00e1kladn\u00ed informace, v\u00fdsledky experiment\u016f<\/h5>\n\t\t\n<style>\n#text-2445156186 {\n  color: rgb(255,255,255);\n}\n#text-2445156186 > * {\n  color: rgb(255,255,255);\n}\n<\/style>\n\t<\/div>\n\t\n\n              <\/div>\n           <\/div>\n                            \n<style>\n#text-box-414654082 {\n  width: 81%;\n}\n#text-box-414654082 .text-box-content {\n  font-size: 100%;\n}\n<\/style>\n    <\/div>\n \n\n        <\/div>\n      <\/div>\n\n            \n<style>\n#banner-1033273354 {\n  padding-top: 500px;\n}\n<\/style>\n  <\/div>\n\n\n\t<div id=\"gap-200675736\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-200675736 {\n  padding-top: 30px;\n}\n<\/style>\n\t<\/div>\n\t\n\n\t<div id=\"gap-1826045410\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1826045410 {\n  padding-top: 30px;\n}\n<\/style>\n\t<\/div>\n\t\n\n<div class=\"row\"  id=\"row-2018228813\">\n\n\n\t<div id=\"col-1708381315\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n\n\t<div id=\"text-3277187699\" class=\"text\">\n\t\t\n\n<p>V\u011aDECK\u00c9 INFORMACE O VLASTNOSTECH A FUNKCI TPA \u2013 STRU\u010cN\u00dd P\u0158EHLED<\/p>\n<p>Thymic Protein A je jedno\u0159et\u011bzcov\u00fd glykoprotein, kter\u00fd je v laborato\u0159i izolovan\u00fd ze supernatantu tk\u00e1\u0148ov\u00e9 kultury sekre\u010dn\u00edch bun\u011bk brzl\u00edkov\u00e9ho epitelu. Molekulov\u00e1 hmotnost je 50kDa, izoelektrick\u00fd bod 6.5. Aminokyselinov\u00e9 slo\u017een\u00ed: Asparagine\/Aspartate\u20138.8%; Threonine\u20133.5%; Serine\u201314.7%; Glutamine\/Glutamate\u201313.3%; Proline\u20132.2%; Glycine\u201325.7%; Alanine\u20136.1%; Valine\u20134.3%; Isoleucine\u20133.4%; Leucine\u20136.3%; Tyrosine\u20132.3%; Phenylalanine\u20132.6%; Histidine \u20132.2%; Lysine\u20134.7%. Pro biologickou aktivitu je kritick\u00e1 vysok\u00e1 \u00a0glykosylace a\u00a0 fosforylace. Struktur\u00e1ln\u011b nikoliv funk\u010dn\u011b m\u00e1 nejbl\u00ed\u017ee k inhibitor\u016fm serinov\u00fdch prote\u00e1z ze superrodiny SERPIN\u016e.\u00a0<\/p>\n<p>P\u0159enesen\u00ed produk\u010dn\u00ed \u010d\u00e1sti brzl\u00edkov\u00e9ho epitelu do tk\u00e1\u0148ov\u00e9 kultury v podob\u011b klon\u016f specifick\u00fdch bun\u011bk umo\u017enilo z\u00edskat kompletn\u00ed p\u0159\u00edrodn\u00ed neporu\u0161en\u00fd protein, kter\u00fd m\u00e1 dramaticky vy\u0161\u0161\u00ed \u00fa\u010dinek na imunitn\u00ed stimulaci, ne\u017e produkty separovan\u00e9 p\u0159\u00edmo ze zv\u00ed\u0159ec\u00edch brzl\u00edk\u016f nebo izolovan\u00e9 separ\u00e1tn\u011b od kompatibiln\u00edch struktur\u00e1ln\u00edch protein\u016f brzl\u00edkov\u00e9ho epitelu, nap\u0159. thymulin.. Protein je citliv\u011b purifikov\u00e1n a upraven tak, aby byla zachov\u00e1na jeho biologick\u00e1 \u00fa\u010dinnost. V\u0161echny ostatn\u00ed proteiny, fragmenty nebo l\u00e1tky jsou b\u011bhem \u010di\u0161t\u011bn\u00ed odfiltrov\u00e1ny a z\u016fstane pouze jedin\u00fd brzl\u00edkov\u00fd protein A, kter\u00fd je n\u00e1sledn\u011b lyofilizov\u00e1n a sm\u00edch\u00e1n z d\u016fvodu jeho stabilizace a zachov\u00e1n\u00ed funk\u010dnosti s maltodextrinem. Nejv\u00fdznamn\u011bj\u0161\u00ed p\u016fsoben\u00ed TPA v t\u011ble je stimulace maturace\u00a0 naivn\u00edch CD4+ lymfocyt\u016f a diferenciace na Th1, stimulace apopt\u00f3zy a stimulace hematop\u00e9zy.<\/p>\n<p>\u00a0<\/p>\n<p>\u00a0<\/p>\n<p><em>V n\u00e1sleduj\u00edc\u00edm textu vych\u00e1z\u00edme ze zn\u011bn\u00ed patent\u016f\u00a0https:\/\/patents.google.com\/patent\/US7776818B2\/en?oq=us7776818, https:\/\/patents.google.com\/patent\/US20070190025A1\/en, https:\/\/patents.google.com\/patent\/US5616554A\/en<\/em><\/p>\n<p>\u00a0<\/p>\n<p>\u00a0<\/p>\n<p>\u00daLOHA TPA V IMUNITN\u00cdM SYST\u00c9MU \u2013 EXPERIMENTY, KLINICK\u00c9 STUDIE<\/p>\n<p>TPA= Epithyme = TISF = S-CELERGIN<\/p>\n<p>TISF stimuluje nebo reguluje proliferaci a diferenciaci lymfocyt\u016f a jin\u00fdch hematopoetick\u00fdch progenitor\u016f, v\u010detn\u011b prekurzor\u016f T bun\u011bk. TISF m\u00e1 nejv\u011bt\u0161\u00ed \u00fa\u010dinek na zv\u00fd\u0161en\u00ed odpov\u011bdi zral\u00fdch T lymfocyt\u016f na infek\u010dn\u00ed agens a na malign\u00ed bu\u0148ky.<br \/>Prim\u00e1rn\u00edm krit\u00e9riem \u00fa\u010dinnosti TISF je jeho schopnost indukovat imunitn\u00ed funkci v populaci bun\u011bk, kter\u00e9 bez t\u00e9to indukce nefunguj\u00ed. Thymocyty se skl\u00e1daj\u00ed z nezral\u00fdch bun\u011bk, kter\u00e9 jsou nefunk\u010dn\u00ed, a zral\u00fdch T bun\u011bk, kter\u00e9 mohou b\u00fdt stimulov\u00e1ny, aby fungovaly proti r\u016fzn\u00fdm \u010dinidl\u016fm, jako jsou viry a n\u00e1dory. P\u016fvodn\u011b byla tato nezral\u00e1 bun\u011b\u010dn\u00e1 populace pou\u017e\u00edv\u00e1na k testov\u00e1n\u00ed faktoru z thymick\u00fdch epiteli\u00e1ln\u00edch bun\u011b\u010dn\u00fdch kultur. Jak je dokumentov\u00e1no v Beardsley, et al., PNAS 80: 6005 (1983), my\u0161\u00ed thymick\u00fd bun\u011b\u010dn\u00fd faktor m\u016f\u017ee vyvolat velmi podstatnou imunitn\u00ed odpov\u011b\u010f v populaci bun\u011bk, kter\u00e9 norm\u00e1ln\u011b nereaguj\u00ed. Zat\u00edmco TISF m\u00e1 m\u00edrn\u00fd, ale rozpoznateln\u00fd stimula\u010dn\u00ed \u00fa\u010dinek na tyto nezral\u00e9 bu\u0148ky, jeho prim\u00e1rn\u00ed p\u016fsoben\u00ed je zam\u011b\u0159eno na zral\u00fd T lymfocyt, co\u017e m\u00e1 za n\u00e1sledek zv\u00fd\u0161enou virovou nebo n\u00e1dorovou imunitu. TISF se li\u0161\u00ed od IL-2 nebo IL-1, kter\u00e9 mohou m\u00edt podobn\u00e9, ale m\u00e9n\u011b dramatick\u00e9 \u00fa\u010dinky. Hlavn\u00ed rozd\u00edl je v tom, \u017ee thymocyty pot\u0159ebuj\u00ed pouze pulzovat TISF po dobu 24 hodin, zat\u00edmco IL-2 mus\u00ed b\u00fdt p\u0159\u00edtomen b\u011bhem 5denn\u00ed induk\u010dn\u00ed f\u00e1ze odpov\u011bdi. TISF m\u00e1 jako prim\u00e1rn\u00ed c\u00edl sv\u00e9ho stimula\u010dn\u00edho \u00fa\u010dinku nereaguj\u00edc\u00ed zral\u00fd T lymfocyt.<br \/>Bylo prok\u00e1z\u00e1no, \u017ee TISF podporuje reakci populace pomocn\u00fdch bun\u011bk. OBR. 1B ukazuje, \u017ee TISF ovliv\u0148uje LYT-2 negativn\u00ed populaci. Naopak kultury postr\u00e1daj\u00edc\u00ed L3T4 pozitivn\u00ed pomocn\u00e9 bu\u0148ky (obr. 1C) nemaj\u00ed \u017e\u00e1dnou aktivitu.<\/p>\n<p>TISF m\u016f\u017ee v\u00fdrazn\u011b zv\u00fd\u0161it nebo zes\u00edlit jak protil\u00e1tkami zprost\u0159edkovan\u00e9, tak zab\u00edje\u010dsk\u00e9 bun\u011b\u010dn\u00e9 reakce proti infek\u010dn\u00edm agens a\/nebo rakovin\u011b prost\u0159ednictv\u00edm sv\u00e9ho \u00fa\u010dinku na bu\u0148ky produkuj\u00edc\u00ed IL-2. Uk\u00e1zalo se, \u017ee obrovsk\u00fd \u00fa\u010dinek TISF je zp\u016fsoben jeho schopnost\u00ed stimulovat produkci IL-2. To je zn\u00e1zorn\u011bno na Obr. 2A blokov\u00e1n\u00edm TISF zes\u00edlen\u00ed aktivity cytotoxick\u00e9ho zabij\u00e1ka protil\u00e1tkou nam\u00ed\u0159enou proti IL-2 receptoru (7D4 nebo 3C7). Irelevantn\u00ed protil\u00e1tky nemaj\u00ed \u017e\u00e1dn\u00fd blokuj\u00edc\u00ed \u00fa\u010dinek (obr. 2B). Z terapeutick\u00e9ho hlediska m\u00e1 smysl rekrutovat pomocn\u00e9 bu\u0148ky, aby vytvo\u0159ily IL-2 v m\u00edst\u011b, kde jsou vy\u017eadov\u00e1ny, sp\u00ed\u0161e ne\u017e injek\u010dn\u011b pod\u00e1vat bolus IL-2, kter\u00fd se rychle \u0159ed\u00ed a degraduje v t\u011blesn\u00e9 tekutin\u011b.<br \/>N\u011bkolik spole\u010dnost\u00ed se pokusilo prok\u00e1zat \u00fa\u010dinnost IL-2, jak jako terapeutickou, tak jako adjuvans. Probl\u00e9my jsou minim\u00e1ln\u011b dvoj\u00ed. Za prv\u00e9, IL-2 je lok\u00e1ln\u00ed, kr\u00e1tkodob\u011b p\u016fsob\u00edc\u00ed cytokin. K dosa\u017een\u00ed fyziologick\u00fdch hladin na po\u017eadovan\u00e9m m\u00edst\u011b, tj. n\u00e1dorov\u00e9 mase, mus\u00ed b\u00fdt pod\u00e1v\u00e1ny nep\u0159irozen\u011b velk\u00e9 d\u00e1vky. T\u00edm se dramaticky zvy\u0161uje pravd\u011bpodobnost, \u017ee pacient bude trp\u011bt vedlej\u0161\u00edmi \u00fa\u010dinky. Za druh\u00e9, IL-2 mus\u00ed b\u00fdt p\u0159\u00edtomen nep\u0159etr\u017eit\u011b po dobu alespo\u0148 p\u011bti dn\u016f, aby se vyvolala \u00fa\u010dinn\u00e1 reakce.<\/p>\n<p>Naproti tomu l\u00e1tka, kterou naz\u00fdv\u00e1me TISF, je norm\u00e1ln\u011b p\u0159\u00edtomna v krvi ve fyziologicky m\u011b\u0159iteln\u00fdch hladin\u00e1ch, s v\u00fdjimkou ur\u010dit\u00fdch chorobn\u00fdch stav\u016f. Jeho zp\u016fsob \u00fa\u010dinku je roz\u0161\u00ed\u0159en na bu\u0148ky imunitn\u00edho syst\u00e9mu v cel\u00e9m t\u011ble. Vzhledem k tomu, \u017ee jde o norm\u00e1ln\u00ed slo\u017eku v ob\u011bhu, lze o\u010dek\u00e1vat jen m\u00e1lo vedlej\u0161\u00edch \u00fa\u010dink\u016f, pokud v\u016fbec n\u011bjak\u00e9. Nejv\u011bt\u0161\u00ed v\u00fdhodou je v\u0161ak to, \u017ee jedin\u00e1 injekce TISF m\u00e1 dlouhodob\u00e9 \u00fa\u010dinky a lze ji pod\u00e1vat samostatn\u011b podobn\u011b jako inzul\u00edn, pouze m\u00e9n\u011b \u010dasto.<\/p>\n<p>Bylo stanoveno, \u017ee TISF nen\u00ed \u017e\u00e1dn\u00fd z d\u0159\u00edve popsan\u00fdch cytokin\u016f. TISF nen\u00ed IL-1 nebo IL-2. Dal\u0161\u00ed testov\u00e1n\u00ed tak\u00e9 uk\u00e1zalo, \u017ee TISF nen\u00ed IL-4. To bylo stanoveno inkubac\u00ed p\u0159irozen\u00fdch zab\u00edje\u010dsk\u00fdch (NK) bun\u011bk bu\u010f s IL-4 nebo TISF purifikovan\u00fdm ze supernatantu kultury a m\u011b\u0159en\u00edm inkorporace [125I]-deoxyuridinu do RNA. L\u00e9\u010dba IL-4 vedla k v\u00fdznamn\u00e9mu zv\u00fd\u0161en\u00ed inkorporace zna\u010dky, zat\u00edmco l\u00e9\u010dba TISF nem\u011bla \u017e\u00e1dn\u00fd \u00fa\u010dinek.<\/p>\n<p>Krom\u011b toho bylo zji\u0161t\u011bno, \u017ee TISF neobsahuje \u017e\u00e1dn\u00fd IL-5 nebo faktor stimuluj\u00edc\u00ed kolonie granulocyt\u016f a makrof\u00e1g\u016f (GM-CSF), jak je uvedeno v tabulce 3. Skute\u010dnost, \u017ee TISF nem\u00e1 \u017e\u00e1dnou p\u0159\u00edmou stimula\u010dn\u00ed aktivitu pro B bu\u0148ky, nazna\u010duje, \u017ee tak\u00e9 nen\u00ed IL-3, IL-6 nebo IL-7. Prob\u00edh\u00e1 dal\u0161\u00ed \u010di\u0161t\u011bn\u00ed a genetick\u00e9 klonov\u00e1n\u00ed, aby se konkr\u00e9tn\u011b identifikovaly podrobn\u00e9 molekul\u00e1rn\u00ed charakteristiky TISF.<\/p>\n\t\t\n<style>\n#text-3277187699 {\n  color: rgb(0,0,0);\n}\n#text-3277187699 > * {\n  color: rgb(0,0,0);\n}\n<\/style>\n\t<\/div>\n\t\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n<\/div>\n<div class=\"row\"  id=\"row-1282703455\">\n\n\n\t<div id=\"col-2000493361\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner text-center\"  >\n\t\t\t\n\t\t\t\n\n\t<div id=\"text-1337245318\" class=\"text\">\n\t\t\n\n\n\t\t\n<style>\n#text-1337245318 {\n  color: rgb(0,0,0);\n}\n#text-1337245318 > * {\n  color: rgb(0,0,0);\n}\n<\/style>\n\t<\/div>\n\t\n<div class=\"row\"  id=\"row-1010839770\">\n\n\n\t<div id=\"col-920021017\" class=\"col medium-6 small-12 large-6\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n\n<div class=\"slider-wrapper relative\" id=\"slider-1707229878\" >\n    <div class=\"slider slider-nav-circle slider-nav-large slider-nav-light slider-style-normal\"\n        data-flickity-options='{            \"cellAlign\": \"center\",            \"imagesLoaded\": true,            \"lazyLoad\": 1,            \"freeScroll\": false,            \"wrapAround\": true,            \"autoPlay\": 6000,            \"pauseAutoPlayOnHover\" : true,            \"prevNextButtons\": true,            \"contain\" : true,            \"adaptiveHeight\" : true,            \"dragThreshold\" : 10,            \"percentPosition\": true,            \"pageDots\": true,            \"rightToLeft\": false,            \"draggable\": true,            \"selectedAttraction\": 0.1,            \"parallax\" : 0,            \"friction\": 0.6        }'\n        >\n        \n\n\t<div class=\"img has-hover x md-x lg-x y md-y lg-y\" id=\"image_1083078074\">\n\t\t\t\t\t\t\t\t<div class=\"img-inner dark\" >\n\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"625\" height=\"861\" src=\"https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/02\/Screenshot-2023-02-02-125029.png\" class=\"attachment-large size-large\" alt=\"\" srcset=\"https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/02\/Screenshot-2023-02-02-125029.png 625w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/02\/Screenshot-2023-02-02-125029-510x703.png 510w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/02\/Screenshot-2023-02-02-125029-218x300.png 218w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/02\/Screenshot-2023-02-02-125029-9x12.png 9w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/02\/Screenshot-2023-02-02-125029-500x689.png 500w\" sizes=\"auto, (max-width: 625px) 100vw, 625px\" \/>\t\t\t\t\t\t\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\n<style>\n#image_1083078074 {\n  width: 100%;\n}\n<\/style>\n\t<\/div>\n\t\n\n\t<div class=\"img has-hover x md-x lg-x y md-y lg-y\" id=\"image_1617870171\">\n\t\t\t\t\t\t\t\t<div class=\"img-inner dark\" >\n\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"651\" height=\"941\" src=\"https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/02\/Screenshot-2023-02-02-125738.png\" class=\"attachment-large size-large\" alt=\"\" srcset=\"https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/02\/Screenshot-2023-02-02-125738.png 651w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/02\/Screenshot-2023-02-02-125738-510x737.png 510w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/02\/Screenshot-2023-02-02-125738-208x300.png 208w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/02\/Screenshot-2023-02-02-125738-8x12.png 8w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/02\/Screenshot-2023-02-02-125738-500x723.png 500w\" sizes=\"auto, (max-width: 651px) 100vw, 651px\" \/>\t\t\t\t\t\t\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\n<style>\n#image_1617870171 {\n  width: 100%;\n}\n<\/style>\n\t<\/div>\n\t\n\n\t<div class=\"img has-hover x md-x lg-x y md-y lg-y\" id=\"image_1045189271\">\n\t\t\t\t\t\t\t\t<div class=\"img-inner dark\" >\n\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"660\" height=\"942\" src=\"https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/02\/Screenshot-2023-02-02-125837.png\" class=\"attachment-large size-large\" alt=\"\" srcset=\"https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/02\/Screenshot-2023-02-02-125837.png 660w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/02\/Screenshot-2023-02-02-125837-510x728.png 510w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/02\/Screenshot-2023-02-02-125837-210x300.png 210w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/02\/Screenshot-2023-02-02-125837-8x12.png 8w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/02\/Screenshot-2023-02-02-125837-500x714.png 500w\" sizes=\"auto, (max-width: 660px) 100vw, 660px\" \/>\t\t\t\t\t\t\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\n<style>\n#image_1045189271 {\n  width: 100%;\n}\n<\/style>\n\t<\/div>\n\t\n\n\t<div class=\"img has-hover x md-x lg-x y md-y lg-y\" id=\"image_905500985\">\n\t\t\t\t\t\t\t\t<div class=\"img-inner dark\" >\n\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"661\" height=\"946\" src=\"https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/02\/Screenshot-2023-02-02-125953.png\" class=\"attachment-large size-large\" alt=\"\" srcset=\"https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/02\/Screenshot-2023-02-02-125953.png 661w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/02\/Screenshot-2023-02-02-125953-510x730.png 510w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/02\/Screenshot-2023-02-02-125953-210x300.png 210w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/02\/Screenshot-2023-02-02-125953-8x12.png 8w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/02\/Screenshot-2023-02-02-125953-500x716.png 500w\" sizes=\"auto, (max-width: 661px) 100vw, 661px\" \/>\t\t\t\t\t\t\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\n<style>\n#image_905500985 {\n  width: 100%;\n}\n<\/style>\n\t<\/div>\n\t\n\n\n     <\/div>\n\n     <div class=\"loading-spin dark large centered\"><\/div>\n\n\t<\/div>\n\n\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n\n<style>\n#row-1010839770 > .col > .col-inner {\n  background-color: rgb(213, 218, 232);\n}\n<\/style>\n<\/div>\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n\n<style>\n#row-1282703455 > .col > .col-inner {\n  background-color: rgb(213, 218, 232);\n}\n<\/style>\n<\/div>\n<div class=\"row\"  id=\"row-320515755\">\n\n\n\t<div id=\"col-530418989\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n\n\t<div id=\"text-2479803543\" class=\"text\">\n\t\t\n\n<p>Bylo prok\u00e1z\u00e1no, \u017ee u ps\u016f TPA zesiluje protil\u00e1tkov\u00e9 reakce na virus vztekliny nejm\u00e9n\u011b p\u011btin\u00e1sobn\u011b. Na grafu \u010d. 3 je zn\u00e1zorn\u011bn \u00fa\u010dinek TPA na titry protil\u00e1tek proti viru vztekliny u ps\u016f o\u010dkovan\u00fdch vakc\u00ednou s usmrcen\u00fdm virem vztekliny. V kontroln\u00ed skupin\u011b, kter\u00e1 byla o\u010dkov\u00e1na vakc\u00ednou usmrcen\u00fdm virem vztekliny potencovanou hlin\u00edkem, dos\u00e1hly titry protil\u00e1tek proti viru vztekliny vrcholu b\u011bhem dvou t\u00fddn\u016f na \u00farovni v\u00fdrazn\u011b pod 250. Zv\u00ed\u0159ata v experiment\u00e1ln\u00ed skupin\u011b vykazovala p\u0159etrv\u00e1vaj\u00edc\u00ed zv\u00fd\u0161en\u00e9 titry, kter\u00e9 dos\u00e1hly vrcholu asi dva t\u00fddny po imunizaci, na \u00farovni p\u0159esahuj\u00edc\u00ed 750.<\/p>\n\t\t\n<style>\n#text-2479803543 {\n  color: rgb(0,0,0);\n}\n#text-2479803543 > * {\n  color: rgb(0,0,0);\n}\n<\/style>\n\t<\/div>\n\t\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n<\/div>\n<div class=\"row\"  id=\"row-1244083318\">\n\n\n\t<div id=\"col-1749841692\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner text-center\" style=\"background-color:rgb(213, 218, 232);\" >\n\t\t\t\n\t\t\t\n\n\t<div id=\"text-1364628275\" class=\"text\">\n\t\t\n\n\n\t\t\n<style>\n#text-1364628275 {\n  color: rgb(0,0,0);\n}\n#text-1364628275 > * {\n  color: rgb(0,0,0);\n}\n<\/style>\n\t<\/div>\n\t\n<div class=\"row\"  id=\"row-1549903054\">\n\n\n\t<div id=\"col-10517137\" class=\"col medium-6 small-12 large-6\"  >\n\t\t\t\t<div class=\"col-inner text-center\" style=\"background-color:rgb(213, 218, 232);\" >\n\t\t\t\n\t\t\t\n\n\t<div class=\"img has-hover x md-x lg-x y md-y lg-y\" id=\"image_1151388945\">\n\t\t\t\t\t\t\t\t<div class=\"img-inner dark\" >\n\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"517\" height=\"650\" src=\"https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/02\/Screenshot-2023-02-01-191945.png\" class=\"attachment-large size-large\" alt=\"\" srcset=\"https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/02\/Screenshot-2023-02-01-191945.png 517w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/02\/Screenshot-2023-02-01-191945-510x641.png 510w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/02\/Screenshot-2023-02-01-191945-239x300.png 239w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/02\/Screenshot-2023-02-01-191945-10x12.png 10w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/02\/Screenshot-2023-02-01-191945-500x629.png 500w\" sizes=\"auto, (max-width: 517px) 100vw, 517px\" \/>\t\t\t\t\t\t\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\n<style>\n#image_1151388945 {\n  width: 100%;\n}\n<\/style>\n\t<\/div>\n\t\n\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n<\/div>\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n<\/div>\n<div class=\"row\"  id=\"row-774073939\">\n\n\n\t<div id=\"col-1814945511\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner text-left\" style=\"background-color:rgba(249, 250, 253, 0);\" >\n\t\t\t\n\t\t\t\n\n\t<div id=\"text-3044555284\" class=\"text\">\n\t\t\n\n<p>Ve druh\u00e9m modelu pou\u017eit\u00e9m k testov\u00e1n\u00ed \u00fa\u010dinnosti TPA byli psi imunizov\u00e1ni virulentn\u00edm virem psinky plus adjuvans bu\u010f hlin\u00edk nebo TPA. O virech psinky (Morbillivirus ) je zn\u00e1mo, \u017ee maj\u00ed imunosupresivn\u00ed \u00fa\u010dinky. \u00da\u010dinnost vakcinace s TPA byla v\u00edce ne\u017e dvojn\u00e1sobn\u00e1.<\/p>\n<p>U my\u0161\u00ed je prim\u00e1rn\u00ed ochrana, stejn\u011b jako u lid\u00ed, zaji\u0161t\u011bna zv\u00fd\u0161en\u00fdmi titry protil\u00e1tek proti hemaglutininov\u00e9mu antigenu (HA). V prim\u00e1rn\u00ed reakci na infekci ch\u0159ipkou byly titry HA u my\u0161\u00ed zv\u00fd\u0161eny 8kr\u00e1t. Titry byly 1:20 u mlad\u00fdch my\u0161\u00ed inokulovan\u00fdch samotn\u00fdm virem a 1:160 u my\u0161\u00ed dost\u00e1vaj\u00edc\u00edch virov\u00e9 inokulace plus TPA. Bu\u0148kou zprost\u0159edkovan\u00e1 odpov\u011b\u010f na ch\u0159ipkov\u00fd virus je rozhoduj\u00edc\u00ed pro zotaven\u00ed z infekce. To je d\u016fle\u017eit\u00e9, proto\u017ee \u201ebun\u011b\u010dn\u00e1 imunitn\u00ed odpov\u011b\u010f \u2013 cell-mediated immune (CMI) response\u201c je zam\u011b\u0159ena na vysoce konzervativn\u00ed, nestruktur\u00e1ln\u00ed genov\u00fd produkt exprimovan\u00fd na infikovan\u00fdch bu\u0148k\u00e1ch, kter\u00fd je spole\u010dn\u00fd v\u0161em zn\u00e1m\u00fdm kmen\u016fm ch\u0159ipky A. Pokud se tedy \u010dlov\u011bk nakaz\u00ed ch\u0159ipkou kv\u016fli genetick\u00e9 variabilit\u011b molekuly HA, r\u00e1zn\u011bj\u0161\u00ed reakce CMI by mohla velmi dob\u0159e zkr\u00e1tit dobu trv\u00e1n\u00ed nemoci, proto\u017ee \u201epam\u011b\u0165ov\u00e1\u201c CMI by byla zk\u0159\u00ed\u017een\u011b reaktivn\u00ed se v\u0161emi ch\u0159ipkov\u00fdmi kmeny.<\/p>\n<p>Za \u00fa\u010delem testov\u00e1n\u00ed t\u00e9to mo\u017enosti byly my\u0161i, kter\u00e9 byly infikov\u00e1ny ch\u0159ipkou s nebo bez TPA , testov\u00e1ny za n\u011bkolik t\u00fddn\u016f na jejich sekund\u00e1rn\u00ed cytotoxickou \u201ekiller\u201c bun\u011b\u010dnou odpov\u011b\u010f proti c\u00edlov\u00fdm bu\u0148k\u00e1m infikovan\u00fdm virem ch\u0159ipky. Aktivita zab\u00edjen\u00ed m\u011b\u0159en\u00e1 l\u00fdzou c\u00edlov\u00fdch bun\u011bk byla zv\u00fd\u0161ena nejm\u00e9n\u011b 9kr\u00e1t u lymfocyt\u016f od p\u0159\u00edjemc\u016f TPA<\/p>\n<p>Bylo prok\u00e1z\u00e1no, \u017ee TPA zvy\u0161uje imunitn\u00ed reaktivitu nebo schopnost reagovat na n\u011bkolik virov\u00fdch onemocn\u011bn\u00ed. Byl proveden experiment, kdy ko\u010dk\u00e1m infikovan\u00fdm FIV byl pod\u00e1v\u00e1n jednou nebo dvakr\u00e1t t\u00fddn\u011b TPA a sledovalo se zlep\u0161en\u00ed stavu imunity.<br \/>Jeden\u00e1ct ko\u010dek ve v\u011bku od jednoho do t\u0159\u00ed let bylo z\u00edsk\u00e1no od Dr. Janet Yamamoto z University of California v Davisu. Ko\u010dky byly experiment\u00e1ln\u011b infikov\u00e1ny kmenem Petaluma FIV jako kontroly ve studii vakc\u00edny. (Viz Pedersen a kol., Science 235: 790-93 (1987).<br \/>Dr. Yamamoto ur\u010dila v\u0161echny ko\u010dky jako FIV pozitivn\u00ed, ale po p\u0159\u00edjezdu do testovac\u00edho za\u0159\u00edzen\u00ed nevykazovaly \u017e\u00e1dn\u00e9 p\u0159\u00edznaky onemocn\u011bn\u00ed. Z\u00e1kladn\u00ed testovac\u00ed protokol je n\u00e1sleduj\u00edc\u00ed:<\/p>\n<p>1. Ko\u010dky byly ponech\u00e1ny dva t\u00fddny v klidu, aby si mohly odpo\u010dinout a aklimatizovaly se.<br \/>2. P\u0159ed zah\u00e1jen\u00edm l\u00e9\u010dby byly odebr\u00e1ny vzorky krve pro stanoven\u00ed z\u00e1kladn\u00edho po\u010dtu lymfocyt\u016f resp. pom\u011br\u016f T4\/T8.<br \/>3. N\u00e1hodn\u011b byly ko\u010dky vybr\u00e1ny do l\u00e9\u010debn\u00e9 (6 ko\u010dek) a kontroln\u00ed (5 ko\u010dek) skupiny.<br \/>4. L\u00e9\u010den\u00e9 skupin\u011b ko\u010dek byl subkut\u00e1nn\u011b aplikov\u00e1n 1,0 ml ko\u010di\u010d\u00edho TPA v purifikovan\u00e9 nebo \u010d\u00e1ste\u010dn\u011b purifikovan\u00e9 form\u011b.<br \/>5. Vzorky krve byly odeb\u00edr\u00e1ny ka\u017ed\u00fd t\u00fdden p\u0159ed ka\u017edou injekc\u00ed a byly sledov\u00e1ny klinick\u00e9 p\u0159\u00edznaky a zaznamen\u00e1v\u00e1ny n\u00e1lezy.<br \/>6. Byl z\u00edsk\u00e1n vzorek kostn\u00ed d\u0159en\u011b a krve pro pou\u017eit\u00ed v testu detekce FIV u l\u00e9\u010den\u00fdch a kontroln\u00edch zv\u00ed\u0159at.<\/p>\n<p>\u0160est ko\u010dek l\u00e9\u010den\u00fdch TISF vyk\u00e1zalo statisticky v\u00fdznamn\u00e9 zkr\u00e1cen\u00ed obdob\u00ed lymfopenie, s n\u00edm\u017e se setk\u00e1v\u00e1me v \u010dasn\u00e9m pr\u016fb\u011bhu onemocn\u011bn\u00ed FIV, ve srovn\u00e1n\u00ed s p\u011bti nel\u00e9\u010den\u00fdmi kontrolami (obr. 6). Klinicky se experiment\u00e1ln\u011b l\u00e9\u010den\u00e1 skupina zotavila mnohem rychleji ze zn\u00e1mek virov\u00fdch infekc\u00ed horn\u00edch cest d\u00fdchac\u00edch, kter\u00e9 vykazovalo v\u0161ech jeden\u00e1ct zv\u00ed\u0159at. Kone\u010dn\u011b vy\u0161et\u0159en\u00ed krve a kostn\u00ed d\u0159en\u011b zv\u00ed\u0159at potvrdilo, \u017ee skupina experiment\u00e1ln\u011b l\u00e9\u010den\u00e1 TISF m\u011bla zlep\u0161en\u00fd virologick\u00fd stav a celularitu d\u0159en\u011b ve srovn\u00e1n\u00ed s kontrolami.<\/p>\n\t\t\n<style>\n#text-3044555284 {\n  color: rgb(0,0,0);\n}\n#text-3044555284 > * {\n  color: rgb(0,0,0);\n}\n<\/style>\n\t<\/div>\n\t\n<div class=\"row\"  id=\"row-1324845793\">\n\n\n\t<div id=\"col-220110390\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner text-center\"  >\n\t\t\t\n\t\t\t\n\n<div class=\"row\"  id=\"row-772755523\">\n\n\n\t<div id=\"col-1203659296\" class=\"col medium-6 small-12 large-6\"  >\n\t\t\t\t<div class=\"col-inner text-center\"  >\n\t\t\t\n\t\t\t\n\n\t<div id=\"gap-1532743061\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1532743061 {\n  padding-top: 30px;\n}\n<\/style>\n\t<\/div>\n\t\n\n\t<div class=\"img has-hover x md-x lg-x y md-y lg-y\" id=\"image_1025148622\">\n\t\t\t\t\t\t\t\t<div class=\"img-inner dark\" >\n\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"656\" height=\"893\" src=\"https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/02\/Screenshot-2023-02-02-131421-1.png\" class=\"attachment-large size-large\" alt=\"\" srcset=\"https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/02\/Screenshot-2023-02-02-131421-1.png 656w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/02\/Screenshot-2023-02-02-131421-1-510x694.png 510w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/02\/Screenshot-2023-02-02-131421-1-220x300.png 220w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/02\/Screenshot-2023-02-02-131421-1-9x12.png 9w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/02\/Screenshot-2023-02-02-131421-1-500x681.png 500w\" sizes=\"auto, (max-width: 656px) 100vw, 656px\" \/>\t\t\t\t\t\t\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\n<style>\n#image_1025148622 {\n  width: 100%;\n}\n<\/style>\n\t<\/div>\n\t\n\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n\n<style>\n#row-772755523 > .col > .col-inner {\n  background-color: rgb(213, 218, 232);\n}\n<\/style>\n<\/div>\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n\n<style>\n#row-1324845793 > .col > .col-inner {\n  background-color: rgb(213, 218, 232);\n}\n<\/style>\n<\/div>\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n<\/div>\n<div class=\"row\"  id=\"row-1292786811\">\n\n\n\t<div id=\"col-1656912798\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n\n\t<div id=\"text-3458822306\" class=\"text\">\n\t\t\n\n<p>V\u00fdsledky l\u00e9\u010dby symptomatick\u00fdch FIV pozitivn\u00edch ko\u010dek na n\u011bkolika soukrom\u00fdch veterin\u00e1rn\u00edch klinik\u00e1ch, kter\u00fdm byl jednou t\u00fddn\u011b injek\u010dn\u011b aplikov\u00e1n TISF jsou n\u00e1sleduj\u00edc\u00ed: V\u0161ech osm ko\u010dek vykazovalo symptomatick\u00e9 zlep\u0161en\u00ed (v\u00fdrazn\u00e9 zlep\u0161en\u00ed gingivitidy, stomatitidy, \u00fastup pr\u016fjmu, v\u011bt\u0161\u00ed chu\u0165 k j\u00eddlu, zastaven\u00fd v\u00fdtok z nosu, zlep\u0161en\u00ed konjunktivitidy, frk\u00e1n\u00ed, hmotnostn\u00ed p\u0159\u00edr\u016fstek a tak\u00e9 zv\u00fd\u0161en\u00fd po\u010det lymfocyt\u016f v perifern\u00ed krvi po l\u00e9\u010db\u011b TISF, nap\u0159. z 9% na 17%, z 15% na 39%, z 19% na 25%\u2026<\/p>\n<p>TISF produkovan\u00fd epiteli\u00e1ln\u00edmi bu\u0148kami thymu skotu byl testov\u00e1n na antivirovou aktivitu proti viru lidsk\u00e9 imunodeficience (HIV). Lymfocyty lidsk\u00e9 perifern\u00ed krve pou\u017eit\u00e9 pro tento in vitro test byly z\u00edsk\u00e1ny od zdrav\u00fdch HIV-negativn\u00edch d\u00e1rc\u016f a byly purifikov\u00e1ny za pou\u017eit\u00ed diskontinu\u00e1ln\u00ed gradientov\u00e9 centrifugace a m\u00e9dia pro separaci lymfocyt\u016f (Organon Teknika). Lymfocyty byly nejprve stimulov\u00e1ny fytohemaglutininem (PHA) a pot\u00e9 byly udr\u017eov\u00e1ny v m\u00e9diu RPMI-1640 a DMEM. Bu\u0148ky z t\u00e9to kultury byly koncentrov\u00e1ny a suspendov\u00e1ny v inokulu zn\u00e1m\u00e9ho kmene HIV (H112-2) po dobu dvou hodin. Bu\u0148ky byly pot\u00e9 promyty, aby se odstranil neabsorbovan\u00fd virus, a byly resuspendov\u00e1ny v \u010derstv\u00e9m m\u00e9diu. 2 x 105 bun\u011bk bylo rozd\u011bleno do jamek 24jamkov\u00e9 desti\u010dky. R\u016fzn\u00e9 koncentrace bovinn\u00edho TISF ve dvojn\u00e1sobn\u00fdch \u0159ed\u011bn\u00edch od 1:5 do 1:160 byly p\u0159id\u00e1ny do jamek obsahuj\u00edc\u00edch infikovan\u00e9 bu\u0148ky a do kontroln\u00edch jamek obsahuj\u00edc\u00edch neinfikovan\u00e9 bu\u0148ky.<br \/>\nInterleukin-2 (IL-2) v koncentrac\u00edch, kter\u00e9 se mezi r\u016fzn\u00fdmi desti\u010dkami m\u011bnily, byl p\u0159id\u00e1n do m\u00e9dia, aby se vyhodnotil \u00fa\u010dinek r\u016fzn\u00fdch \u00farovn\u00ed stimulace lymfocyt\u016f. Na ka\u017ed\u00e9 plotn\u011b byly zahrnuty bun\u011b\u010dn\u00e9 kontroly (neo\u0161et\u0159en\u00e9, neinfikovan\u00e9) a virov\u00e9 kontroly (nel\u00e9\u010den\u00e9, infikovan\u00e9). Dideoxyinosin (DDI), zn\u00e1m\u00e9 siln\u00e9 anti-HIV \u010dinidlo, byl testov\u00e1n jako pozitivn\u00ed kontrola. Desti\u010dky byly kultivov\u00e1ny po dobu 5 dn\u016f p\u0159i 37 \u00b0C ve zvlh\u010den\u00e9 atmosf\u00e9\u0159e 5 % C02. P\u00e1t\u00fd nebo \u0161est\u00fd den po infekci byl odebr\u00e1n vzorek supernatantov\u00e9ho m\u00e9dia z ka\u017ed\u00e9 testovac\u00ed jamky a testov\u00e1n na koncentraci HIV p24 j\u00e1drov\u00e9ho antigenu pomoc\u00ed ELISA (Dupont Company, Boston, MA). V\u00fdsledky t\u011bchto stanoven\u00ed zn\u00e1zorn\u011bn\u00e9 jako procento sn\u00ed\u017een\u00ed koncentrace antigenu p24 ve srovn\u00e1n\u00ed s neo\u0161et\u0159en\u00fdmi virov\u00fdmi kontrolami jsou uvedeny v tabulce V.<\/p>\n<p>\u00da\u010dinek TISF na bun\u011b\u010dn\u00fd r\u016fst byl hodnocen, aby se ov\u011b\u0159ilo, \u017ee virov\u00e1 inhibice, kterou produkoval, nebyla pouze odrazem cytotoxicity proti samotn\u00fdm infikovan\u00fdm bu\u0148k\u00e1m, sp\u00ed\u0161e ne\u017e antivirov\u00fdm \u00fa\u010dinkem. K identifikaci a kvantifikaci \u017eivotaschopn\u00fdch bun\u011bk z neinfikovan\u00fdch jamek p\u0159i ka\u017ed\u00e9m \u0159ed\u011bn\u00ed d\u00e1vky TISF byl pou\u017eit test s barvivem MTT-formazan. Tento test se op\u00edr\u00e1 o redukci MTT tetrazoliov\u00e9 soli \u017eiv\u00fdmi bu\u0148kami za vzniku modr\u00e9ho formazanov\u00e9ho produktu. Jak je uvedeno v tabulce VI, zat\u00edmco ur\u010dit\u00e1 cytotoxicita byla pozorov\u00e1na p\u0159i vysok\u00fdch d\u00e1vk\u00e1ch TISF v bu\u0148k\u00e1ch pod vysokou stimulac\u00ed IL-2, p\u0159i ni\u017e\u0161\u00edch koncentrac\u00edch a ni\u017e\u0161\u00edch hladin\u00e1ch IL-2, kter\u00e9 jsou l\u00e9pe dosa\u017eiteln\u00e9 v terapeutick\u00fdch situac\u00edch, byla zaznamen\u00e1na v\u00fdznamn\u00e1 virov\u00e1 inhibice i v p\u0159\u00edtomnosti zv\u00fd\u0161en\u00e9ho r\u016fstu bun\u011bk<\/p>\n<p>Tato studie prok\u00e1zala v\u00fdrazn\u00e9 sn\u00ed\u017een\u00ed virov\u00e9 z\u00e1t\u011b\u017ee lidsk\u00fdch lymfocyt\u016f infikovan\u00fdch HIV zp\u016fsobenou TISF, kter\u00e9 nebylo zp\u016fsobeno pouze cytotoxick\u00fdm \u00fa\u010dinkem. Zat\u00edmco antivirov\u00fd \u00fa\u010dinek TISF byl m\u00e9n\u011b siln\u00fd ne\u017e \u00fa\u010dinek DDI, TISF si udr\u017eel svou virovou inhibici i za podm\u00ednek, kdy tak\u00e9 stimuloval zv\u00fd\u0161en\u00ed po\u010dtu lymfocyt\u016f.<\/p>\n<p>Table V.<\/p>\n\t\t\n<style>\n#text-3458822306 {\n  color: rgb(0,0,0);\n}\n#text-3458822306 > * {\n  color: rgb(0,0,0);\n}\n<\/style>\n\t<\/div>\n\t\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n<\/div>\n<div class=\"row\"  id=\"row-1354331190\">\n\n\n\t<div id=\"col-412939082\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n\n<div class=\"row\"  id=\"row-14157725\">\n\n\n\t<div id=\"col-1793825919\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n\n<pre class=\"wp-block-preformatted has-small-font-size\">                                  TABLE V<\/p>\n<div class=\"is-divider divider clearfix\" ><\/div>\n\n<div class=\"is-divider divider clearfix\" ><\/div>\n\n<div class=\"is-divider divider clearfix\" ><\/div>\n\n<div class=\"is-divider divider clearfix\" ><\/div>\n\n<div class=\"is-divider divider clearfix\" ><\/div>\n\n<div class=\"is-divider divider clearfix\" ><\/div>\n\n<div class=\"is-divider divider clearfix\" ><\/div>\n\n<div class=\"is-divider divider clearfix\" ><\/div>\n\n<div class=\"is-divider divider clearfix\" ><\/div>\n\n<div class=\"is-divider divider clearfix\" ><\/div>\n\n<div class=\"is-divider divider clearfix\" ><\/div>\n\n<div class=\"is-divider divider clearfix\" ><\/div>\n\n<div class=\"is-divider divider clearfix\" ><\/div>\n\n<div class=\"is-divider divider clearfix\" ><\/div>\n\n<div class=\"is-divider divider clearfix\" ><\/div>\n\n<p>ANTIVIRAL ACTIVITY OF TISF IN THE PRESENCE OF IL-2<br \/>\n           1.0 u\/ml   .32 u\/ml   0.1 u\/ml<br \/>\n           Antiviral  Antiviral  Antiviral<br \/>\n           Activity   Activity   Activity<br \/>\nIL-2       p24  Reduction<br \/>\n                      p24  Reduction<br \/>\n                                 p24  Reduction<br \/>\nDOSAGE     (ng\/ml)<br \/>\n                (%)   (ng\/ml)<br \/>\n                           (%)   (ng\/ml)<br \/>\n                                      (%)<\/p>\n<div class=\"is-divider divider clearfix\" ><\/div>\n\n<div class=\"is-divider divider clearfix\" ><\/div>\n\n<div class=\"is-divider divider clearfix\" ><\/div>\n\n<div class=\"is-divider divider clearfix\" ><\/div>\n\n<div class=\"is-divider divider clearfix\" ><\/div>\n\n<div class=\"is-divider divider clearfix\" ><\/div>\n\n<div class=\"is-divider divider clearfix\" ><\/div>\n\n<div class=\"is-divider divider clearfix\" ><\/div>\n\n<div class=\"is-divider divider clearfix\" ><\/div>\n\n<div class=\"is-divider divider clearfix\" ><\/div>\n\n<div class=\"is-divider divider clearfix\" ><\/div>\n\n<div class=\"is-divider divider clearfix\" ><\/div>\n\n<div class=\"is-divider divider clearfix\" ><\/div>\n\n<div class=\"is-divider divider clearfix\" ><\/div>\n\n<div class=\"is-divider divider clearfix\" ><\/div>\n\n<p>TISF 1:5   432.9<br \/>\n                27.8  247.3<br \/>\n                           33.6  90.13<br \/>\n                                      46.9<br \/>\nTISF 1:10  517.3<br \/>\n                13.7  292.4<br \/>\n                           21.5  92.93<br \/>\n                                      45.2<br \/>\nTISF 1:20  531.9<br \/>\n                11.3  307.2<br \/>\n                           17.6  98.96<br \/>\n                                      41.7<br \/>\nTISF 1:40  579.3<br \/>\n                3.4   313.7<br \/>\n                           15.8  111.6<br \/>\n                                      34.2<br \/>\nTISF 1:80  571.2<br \/>\n                4.7   287.2<br \/>\n                           22.9  103.7<br \/>\n                                      38.9<br \/>\nTISF 1:160 602.2<br \/>\n                -0.4  309.6<br \/>\n                           16.9  115.5<br \/>\n                                      31.9<br \/>\nVIRAL CONTROL<br \/>\n           599.6<br \/>\n                --    372.6<br \/>\n                           --    169.6<br \/>\n                                      --<br \/>\nDDI 100 \u03bcM<br \/>\n           0.312<br \/>\n                99.96   ND+<br \/>\n                           --    ND   --<br \/>\nDDI 31.6 \u03bcM<br \/>\n           4.431<br \/>\n                99.4  ND   --    ND   --<br \/>\nDDI 10 \u03bcM<br \/>\n           158.8<br \/>\n                79.0  ND   --    ND   --<br \/>\nDDI 3.16 \u03bcM<br \/>\n           406.4<br \/>\n                46.2  ND   --    ND   --<br \/>\nDDI 1 \u03bcM<br \/>\n           529.1<br \/>\n                30.0  ND   --    ND   --<br \/>\nDDI .316 \u03bcM<br \/>\n           551.7<br \/>\n                27.0  ND   --    ND   --<br \/>\nVIRAL CONTROL<br \/>\n           755.6<br \/>\n                --    ND   --    ND   --<\/p>\n<div class=\"is-divider divider clearfix\" ><\/div>\n\n<div class=\"is-divider divider clearfix\" ><\/div>\n\n<div class=\"is-divider divider clearfix\" ><\/div>\n\n<div class=\"is-divider divider clearfix\" ><\/div>\n\n<div class=\"is-divider divider clearfix\" ><\/div>\n\n<div class=\"is-divider divider clearfix\" ><\/div>\n\n<div class=\"is-divider divider clearfix\" ><\/div>\n\n<div class=\"is-divider divider clearfix\" ><\/div>\n\n<div class=\"is-divider divider clearfix\" ><\/div>\n\n<div class=\"is-divider divider clearfix\" ><\/div>\n\n<div class=\"is-divider divider clearfix\" ><\/div>\n\n<div class=\"is-divider divider clearfix\" ><\/div>\n\n<div class=\"is-divider divider clearfix\" ><\/div>\n\n<div class=\"is-divider divider clearfix\" ><\/div>\n\n<div class=\"is-divider divider clearfix\" ><\/div>\n\n<p>*HIV p24 core antigen measured by ELISA<br \/>\n +ND = not determined        <\/p>\n<pre class=\"wp-block-preformatted has-small-font-size\">                                 TABLE VI<\/p>\n<div class=\"is-divider divider clearfix\" ><\/div>\n\n<div class=\"is-divider divider clearfix\" ><\/div>\n\n<div class=\"is-divider divider clearfix\" ><\/div>\n\n<div class=\"is-divider divider clearfix\" ><\/div>\n\n<div class=\"is-divider divider clearfix\" ><\/div>\n\n<div class=\"is-divider divider clearfix\" ><\/div>\n\n<div class=\"is-divider divider clearfix\" ><\/div>\n\n<div class=\"is-divider divider clearfix\" ><\/div>\n\n<div class=\"is-divider divider clearfix\" ><\/div>\n\n<div class=\"is-divider divider clearfix\" ><\/div>\n\n<div class=\"is-divider divider clearfix\" ><\/div>\n\n<div class=\"is-divider divider clearfix\" ><\/div>\n\n<div class=\"is-divider divider clearfix\" ><\/div>\n\n<div class=\"is-divider divider clearfix\" ><\/div>\n\n<div class=\"is-divider divider clearfix\" ><\/div>\n\n<p>EFFECT OF TISF ON CELL GROWTH IN THE PRESENCE OF IL-2<br \/>\n          1.0 u\/ml .32 u\/ml 0.1 u\/ml<br \/>\n          Cell     Cell     Cell<br \/>\n          Viability<br \/>\n                   Viability<br \/>\n                            Viability<br \/>\nIL-2      MTT (%) Cell<br \/>\n                   MTT (%) Cell<br \/>\n                            MTT (%) Cell<br \/>\nDOSAGE    Abs Growth<br \/>\n                   Abs Growth<br \/>\n                            Abs Growth<\/p>\n<div class=\"is-divider divider clearfix\" ><\/div>\n\n<div class=\"is-divider divider clearfix\" ><\/div>\n\n<div class=\"is-divider divider clearfix\" ><\/div>\n\n<div class=\"is-divider divider clearfix\" ><\/div>\n\n<div class=\"is-divider divider clearfix\" ><\/div>\n\n<div class=\"is-divider divider clearfix\" ><\/div>\n\n<div class=\"is-divider divider clearfix\" ><\/div>\n\n<div class=\"is-divider divider clearfix\" ><\/div>\n\n<div class=\"is-divider divider clearfix\" ><\/div>\n\n<div class=\"is-divider divider clearfix\" ><\/div>\n\n<div class=\"is-divider divider clearfix\" ><\/div>\n\n<div class=\"is-divider divider clearfix\" ><\/div>\n\n<div class=\"is-divider divider clearfix\" ><\/div>\n\n<div class=\"is-divider divider clearfix\" ><\/div>\n\n<div class=\"is-divider divider clearfix\" ><\/div>\n\n<p>TISF 1:5  0.994<br \/>\n              92.6 0.761<br \/>\n                       85.1 0.371<br \/>\n                                81.7<br \/>\nTISF 1:10 1.029<br \/>\n              95.8 0.818<br \/>\n                       91.5 0.433<br \/>\n                                95.4<br \/>\nTISF 1:20 1.059<br \/>\n              98.6 0.828<br \/>\n                       92.6 0.457<br \/>\n                                102.9<br \/>\nTISF 1:40 1.085<br \/>\n              101.0<br \/>\n                   0.866<br \/>\n                       96.9 0.508<br \/>\n                                111.9<br \/>\nTISF 1:80 1.07<br \/>\n              99.6 0.872<br \/>\n                       97.5 0.541<br \/>\n                                119.2<br \/>\nTISF 1:160<br \/>\n          1.129<br \/>\n              105.1<br \/>\n                   0.889<br \/>\n                       99.4 0.544<br \/>\n                                119.8<br \/>\nCELL CONTROL<br \/>\n          1.074<br \/>\n              100.0<br \/>\n                   0.894<br \/>\n                       100.0<br \/>\n                            0.454<br \/>\n                                100.0<br \/>\nDDI 100 \u03bcM<br \/>\n          0.885<br \/>\n              74.9   ND+<br \/>\n                       --   ND  --<br \/>\nDDI 31.6 \u03bcM<br \/>\n          1.096<br \/>\n              92.7 ND  --   ND  --<br \/>\nDDI 10 \u03bcM<br \/>\n          1.067<br \/>\n              90.3 ND  --   ND  --<br \/>\nDDI 3.16 \u03bcM<br \/>\n          1.077<br \/>\n              91.1 ND  --   ND  --<br \/>\nDDI 1 \u03bcM<br \/>\n          1.1 93.3 ND  --   ND  --<br \/>\nDDI .316 \u03bcM<br \/>\n          1.169<br \/>\n              98.9 ND  --   ND  --<br \/>\nCELL CONTROL<br \/>\n          1.182<br \/>\n              100.0<br \/>\n                   ND  --   ND  --<\/p>\n<div class=\"is-divider divider clearfix\" ><\/div>\n\n<div class=\"is-divider divider clearfix\" ><\/div>\n\n<div class=\"is-divider divider clearfix\" ><\/div>\n\n<div class=\"is-divider divider clearfix\" ><\/div>\n\n<div class=\"is-divider divider clearfix\" ><\/div>\n\n<div class=\"is-divider divider clearfix\" ><\/div>\n\n<div class=\"is-divider divider clearfix\" ><\/div>\n\n<div class=\"is-divider divider clearfix\" ><\/div>\n\n<div class=\"is-divider divider clearfix\" ><\/div>\n\n<div class=\"is-divider divider clearfix\" ><\/div>\n\n<div class=\"is-divider divider clearfix\" ><\/div>\n\n<div class=\"is-divider divider clearfix\" ><\/div>\n\n<div class=\"is-divider divider clearfix\" ><\/div>\n\n<div class=\"is-divider divider clearfix\" ><\/div>\n\n<div class=\"is-divider divider clearfix\" ><\/div>\n\n<p>*MTT formazan absorption by living cells<br \/>\n +ND = not determined    <\/pre>\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n<\/div>\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n\n<style>\n#row-1354331190 > .col > .col-inner {\n  background-color: rgb(213, 218, 232);\n}\n<\/style>\n<\/div>\n<div class=\"row\"  id=\"row-2045859099\">\n\n\n\t<div id=\"col-287881979\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner text-left\"  >\n\t\t\t\n\t\t\t\n\n\t<div id=\"text-23431002\" class=\"text\">\n\t\t\n\n<p>TPA STIMULACE HEMATOPO\u00c9ZY<\/p>\n<p>TPA pozitivn\u011b ovliv\u0148uje hematopo\u00e9zu pravd\u011bpodobn\u011b mechanismem p\u016fsoben\u00ed na stimulaci CD4+ lymfocyt\u016f. CD4+ lymfocyty reguluj\u00ed produkci v\u0161ech typ\u016f krevn\u00edch bun\u011bk v kostn\u00ed d\u0159eni, v\u010detn\u011b \u010derven\u00fdch krvinek, krevn\u00edch desti\u010dek a granulocyt\u016f. Deficit CD-4 lymfocyt\u016f by tedy mohl v\u00e9st k pancytopenii pozorovan\u00e9 u subjekt\u016f s oslabenou imunitou, v\u010detn\u011b pacient\u016f s rakovinou podstupuj\u00edc\u00edch chemoterapii nebo u virov\u00fdch nebo jinak chemicky vyvolan\u00fdch stav\u016f. TISF je nezbytn\u00fd pro stimulaci zral\u00fdch T-lymfocyt\u016f, co\u017e vede ke zv\u00fd\u0161en\u00e9 antivirov\u00e9 nebo protin\u00e1dorov\u00e9 aktivit\u011b. Je pops\u00e1na jeho \u00fa\u010dinnost pro l\u00e9\u010dbu stav\u016f charakterizovan\u00fdch nedostatkem alespo\u0148 jednoho typu krevn\u00edch bun\u011bk vybran\u00fdch ze skupiny sest\u00e1vaj\u00edc\u00ed z \u010derven\u00fdch krvinek, krevn\u00edch desti\u010dek a granulocyt\u016f. TISF poskytuje \u00falevu od t\u011bchto stav\u016f t\u00edm, \u017ee stimuluje tvorbu v\u00edce krevn\u00edch bun\u011bk typu pot\u0159ebn\u00e9ho ke zm\u00edrn\u011bn\u00ed takov\u00e9ho nedostatku :<\/p>\n<p>Pou\u017eit\u00edm postup\u016f popsan\u00fdch v T. R. Ulrich, et al., Blood 86, 971-76 (1995), byly my\u0161i l\u00e9\u010deny chemoterapeutick\u00fdm \u010dinidlem samotn\u00fdm nebo \u010dinidlem plus TISF. Hladiny krevn\u00edch desti\u010dek pak byly stanoveny pro ka\u017ed\u00fd subjekt ka\u017ed\u00fdch n\u011bkolik dn\u00ed po l\u00e9\u010db\u011b. \u010cty\u0159i dny po l\u00e9\u010db\u011b v\u0161echna zv\u00ed\u0159ata vykazovala podstatn\u00fd pokles hladin krevn\u00edch desti\u010dek v pr\u016fm\u011bru na m\u00e9n\u011b ne\u017e polovinu \u00farovn\u011b p\u0159ed l\u00e9\u010dbou. N\u00e1sledn\u011b subjekty, kter\u00e9 nedostaly TISF, vykazovaly malou zm\u011bnu od 4. do 19. dne. Subjekty l\u00e9\u010den\u00e9 TISF vykazovaly statisticky v\u00fdznamn\u00e9 zlep\u0161en\u00ed hladin krevn\u00edch desti\u010dek do 7. dne a do 13. dne se jejich krevn\u00ed desti\u010dky vr\u00e1tily na \u00farove\u0148 p\u0159ed l\u00e9\u010dbou.<\/p>\n<p>OBR. 5 je graf poklesu po\u010dtu krevn\u00edch desti\u010dek a zotaven\u00ed u my\u0161\u00ed, u kter\u00fdch byl nedostatek krevn\u00edch desti\u010dek indukov\u00e1n chemoterapeutickou l\u00e9\u010dbou, jak je pops\u00e1no v T. R. Ulrich a kol., Blood 86, 971-71 (1995). Ukazuje, \u017ee my\u0161i, kter\u00e9 dost\u00e1valy TISF (ozna\u010dovan\u00fd jako S-Celergin) spolu s chemoterapi\u00ed, se zotavily na \u00farove\u0148 po\u010dtu krevn\u00edch desti\u010dek p\u0159ed l\u00e9\u010dbou b\u011bhem p\u0159ibli\u017en\u011b dvou t\u00fddn\u016f, zat\u00edmco my\u0161i, kter\u00e9 nedost\u00e1valy TISF, vykazovaly po 19 dnech malou obnovu hladin krevn\u00edch desti\u010dek.<\/p>\n\t\t\n<style>\n#text-23431002 {\n  color: rgb(0,0,0);\n}\n#text-23431002 > * {\n  color: rgb(0,0,0);\n}\n<\/style>\n\t<\/div>\n\t\n<div class=\"row\"  id=\"row-1968472603\">\n\n\n\t<div id=\"col-2007843614\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner text-center\" style=\"background-color:rgb(213, 218, 232);\" >\n\t\t\t\n\t\t\t\n\n<div class=\"row\"  id=\"row-985635629\">\n\n\n\t<div id=\"col-1869032214\" class=\"col medium-8 small-12 large-8\"  >\n\t\t\t\t<div class=\"col-inner text-center\"  >\n\t\t\t\n\t\t\t\n\n\t<div id=\"gap-2061709766\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-2061709766 {\n  padding-top: 30px;\n}\n<\/style>\n\t<\/div>\n\t\n\n\t<div class=\"img has-hover x md-x lg-x y md-y lg-y\" id=\"image_1174555060\">\n\t\t\t\t\t\t\t\t<div class=\"img-inner dark\" >\n\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"1020\" height=\"808\" src=\"https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/US20070190025A1-20070816-D00003rot-1024x811.png\" class=\"attachment-large size-large\" alt=\"\" srcset=\"https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/US20070190025A1-20070816-D00003rot-1024x811.png 1024w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/US20070190025A1-20070816-D00003rot-510x404.png 510w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/US20070190025A1-20070816-D00003rot-300x238.png 300w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/US20070190025A1-20070816-D00003rot-768x609.png 768w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/US20070190025A1-20070816-D00003rot-1536x1217.png 1536w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/US20070190025A1-20070816-D00003rot-15x12.png 15w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/US20070190025A1-20070816-D00003rot-500x396.png 500w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/US20070190025A1-20070816-D00003rot-800x634.png 800w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/US20070190025A1-20070816-D00003rot-1280x1014.png 1280w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/US20070190025A1-20070816-D00003rot.png 1893w\" sizes=\"auto, (max-width: 1020px) 100vw, 1020px\" \/>\t\t\t\t\t\t\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\n<style>\n#image_1174555060 {\n  width: 100%;\n}\n<\/style>\n\t<\/div>\n\t\n\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n<\/div>\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n\n<style>\n#row-1968472603 > .col > .col-inner {\n  background-color: rgb(213, 218, 232);\n}\n<\/style>\n<\/div>\n<div class=\"row\"  id=\"row-2090745937\">\n\n\n\t<div id=\"col-1035637401\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n\n\t<div id=\"text-2008631137\" class=\"text\">\n\t\t\n\n<p>V\u00fdsledky aplikace TPA ko\u010dk\u00e1m infikovan\u00fdm FeLV nebo FIV:<\/p>\n<p>OBR. 1 ukazuje zv\u00fd\u0161en\u00fd po\u010det lymfocyt\u016f;<\/p>\n<p>OBR. 2 ukazuje zv\u00fd\u0161en\u00fd po\u010det \u010derven\u00fdch krvinek; a<\/p>\n<p>OBR. 3 ukazuje zv\u00fd\u0161en\u00fd po\u010det granulocyt\u016f. V ka\u017ed\u00e9m p\u0159\u00edpad\u011b obr\u00e1zky ukazuj\u00ed, \u017ee zv\u00ed\u0159ata se specifick\u00fdm nedostatkem krevn\u00edch bun\u011bk vykazovala podstatn\u00e9 zlep\u0161en\u00ed po jedn\u00e9 d\u00e1vce TISF, p\u0159i\u010dem\u017e nejv\u011bt\u0161\u00ed n\u00e1r\u016fst byl pozorov\u00e1n u zv\u00ed\u0159at se z\u00e1va\u017en\u00fdmi nedostatky.<\/p>\n<p>OBR. 4 ilustruje zv\u00fd\u0161en\u00ed po\u010dtu krevn\u00edch desti\u010dek zp\u016fsoben\u00e9 pod\u00e1v\u00e1n\u00edm TISF 23 ko\u010dk\u00e1m infikovan\u00fdm bu\u010f FIV nebo FeLV. Ukazuje pr\u016fm\u011brn\u00fd n\u00e1r\u016fst po\u010dtu krevn\u00edch desti\u010dek o 200 %.<\/p>\n\t\t\n<style>\n#text-2008631137 {\n  color: rgb(0,0,0);\n}\n#text-2008631137 > * {\n  color: rgb(0,0,0);\n}\n<\/style>\n\t<\/div>\n\t\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n<\/div>\n<div class=\"row\"  id=\"row-106375757\">\n\n\n\t<div id=\"col-223006639\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner text-center\" style=\"background-color:rgb(213, 218, 232);\" >\n\t\t\t\n\t\t\t\n\n<div class=\"row\"  id=\"row-1361882287\">\n\n\n\t<div id=\"col-450131379\" class=\"col medium-8 small-12 large-8\"  >\n\t\t\t\t<div class=\"col-inner text-center\"  >\n\t\t\t\n\t\t\t\n\n\t<div class=\"img has-hover x md-x lg-x y md-y lg-y\" id=\"image_292833065\">\n\t\t\t\t\t\t\t\t<div class=\"img-inner dark\" >\n\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"692\" height=\"1024\" src=\"https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/US20070190025A1-20070816-D00001rot-692x1024.png\" class=\"attachment-large size-large\" alt=\"\" srcset=\"https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/US20070190025A1-20070816-D00001rot-692x1024.png 692w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/US20070190025A1-20070816-D00001rot-510x755.png 510w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/US20070190025A1-20070816-D00001rot-203x300.png 203w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/US20070190025A1-20070816-D00001rot-768x1136.png 768w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/US20070190025A1-20070816-D00001rot-1038x1536.png 1038w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/US20070190025A1-20070816-D00001rot-1384x2048.png 1384w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/US20070190025A1-20070816-D00001rot-8x12.png 8w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/US20070190025A1-20070816-D00001rot-500x740.png 500w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/US20070190025A1-20070816-D00001rot-800x1184.png 800w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/US20070190025A1-20070816-D00001rot-1280x1894.png 1280w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/US20070190025A1-20070816-D00001rot.png 1401w\" sizes=\"auto, (max-width: 692px) 100vw, 692px\" \/>\t\t\t\t\t\t\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\n<style>\n#image_292833065 {\n  width: 100%;\n}\n<\/style>\n\t<\/div>\n\t\n\n\t<div class=\"img has-hover x md-x lg-x y md-y lg-y\" id=\"image_782543494\">\n\t\t\t\t\t\t\t\t<div class=\"img-inner dark\" >\n\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"1020\" height=\"587\" src=\"https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/US20070190025A1-20070816-D00002-rot-1024x589.png\" class=\"attachment-large size-large\" alt=\"\" srcset=\"https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/US20070190025A1-20070816-D00002-rot-1024x589.png 1024w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/US20070190025A1-20070816-D00002-rot-510x293.png 510w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/US20070190025A1-20070816-D00002-rot-300x173.png 300w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/US20070190025A1-20070816-D00002-rot-768x442.png 768w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/US20070190025A1-20070816-D00002-rot-18x10.png 18w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/US20070190025A1-20070816-D00002-rot-500x288.png 500w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/US20070190025A1-20070816-D00002-rot-800x460.png 800w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/US20070190025A1-20070816-D00002-rot-1280x736.png 1280w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/US20070190025A1-20070816-D00002-rot.png 1351w\" sizes=\"auto, (max-width: 1020px) 100vw, 1020px\" \/>\t\t\t\t\t\t\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\n<style>\n#image_782543494 {\n  width: 100%;\n}\n<\/style>\n\t<\/div>\n\t\n\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n<\/div>\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n\n<style>\n#row-106375757 > .col > .col-inner {\n  background-color: rgb(213, 218, 232);\n}\n<\/style>\n<\/div>\n<div class=\"row\"  id=\"row-154477048\">\n\n\n\t<div id=\"col-1976935527\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner text-left\"  >\n\t\t\t\n\t\t\t\n\n\t<div id=\"text-2966089267\" class=\"text\">\n\t\t\n\n<p>TPA STIMULUJE BUN\u011a\u010cNOU APOPT\u00d3ZU<br \/>Krom\u011b schopnosti stimulovat hematopo\u00e9zu bylo zji\u0161t\u011bno, \u017ee TISF je tak\u00e9 schopen iniciovat apopt\u00f3zu v n\u011bkter\u00fdch bun\u011b\u010dn\u00fdch populac\u00edch, v\u010detn\u011b ur\u010dit\u00fdch typ\u016f krevn\u00edch bun\u011bk. Zejm\u00e9na bylo zji\u0161t\u011bno, \u017ee TISF selektivn\u011b zp\u016fsobuje bun\u011b\u010dnou smrt nebo zastaven\u00ed r\u016fstu tk\u00e1n\u011b u aberantn\u00edch T-bun\u011bk, jako jsou lymfomov\u00e9 bu\u0148ky, lymfocyty, kter\u00e9 nesou virus HIV a leukemick\u00e9 bu\u0148ky. I kdy\u017e se uv\u00e1d\u00ed, \u017ee je schopen stimulovat imunitn\u00ed odpov\u011b\u010f, kter\u00e1 by teoreticky mohla c\u00edlit na malign\u00ed bu\u0148ky bylo zji\u0161t\u011bno, \u017ee TISF m\u016f\u017ee selektivn\u011b zp\u016fsobit bun\u011b\u010dnou smrt v ohro\u017een\u00fdch T-bu\u0148k\u00e1ch v nep\u0159\u00edtomnosti jak\u00e9koli imunitn\u00ed reakce, jak bylo prok\u00e1z\u00e1no experimenty in vitro.<\/p>\n<p>TISF je tedy mo\u017en\u00e9 pou\u017e\u00edt k l\u00e9\u010db\u011b poruch charakterizovan\u00fdch produkc\u00ed, v\u00fdvojem nebo aktivitou aberantn\u00edch T-bun\u011bk, proto\u017ee funguje mechanismem nez\u00e1visl\u00fdm na stimulaci imunitn\u00ed odpov\u011bdi d\u0159\u00edve spojen\u00e9 s TISF. Poskytuje zp\u016fsoby l\u00e9\u010dby takov\u00fdch stav\u016f u jedinc\u016f s oslabenou imunitou, kde by se neo\u010dek\u00e1valo, \u017ee by l\u00e9\u010dba spol\u00e9haj\u00edc\u00ed na stimulaci imunitn\u00ed odpov\u011bdi subjektu dob\u0159e fungovala. Nap\u0159\u00edklad se zvl\u00e1\u0161t\u011b dob\u0159e hod\u00ed k l\u00e9\u010db\u011b jedinc\u016f s poruchou imunity, jako je HIV, a k l\u00e9\u010db\u011b jedinc\u016f, kte\u0159\u00ed sou\u010dasn\u011b dost\u00e1vaj\u00ed imunosupresivn\u00ed l\u00e9ky. Peptidy TISF jsou tedy u\u017eite\u010dn\u00e9 pro l\u00e9\u010dbu t\u011bchto poruch, kter\u00e9 zahrnuj\u00ed r\u016fzn\u00e9 T-bun\u011b\u010dn\u00e9 lymfomy, jako je mycosis fungoides, T-bun\u011b\u010dn\u00e9 leuk\u00e9mie a n\u011bkter\u00e9 virov\u00e9 infekce, jako je HIV, kter\u00e9 jsou p\u0159echov\u00e1v\u00e1ny T-bu\u0148kami.<\/p>\n<p>TISF inhibuje bun\u011b\u010dn\u00fd r\u016fst v kultu\u0159e lymfomov\u00fdch bun\u011bk zp\u016fsobem z\u00e1visl\u00fdm na d\u00e1vce, jak bylo prok\u00e1z\u00e1no experimenty s inkorporac\u00ed 3H-thymidinu. Bylo tak\u00e9 prok\u00e1z\u00e1no, \u017ee zvy\u0161uje m\u00edru bun\u011b\u010dn\u00e9 smrti mezi lymfocyty infikovan\u00fdmi virem HIV. V takov\u00fdch bu\u0148k\u00e1ch TISF tak\u00e9 zpomalil produkci viru. Krom\u011b toho, kdy\u017e byly bu\u0148ky lidsk\u00e9 myelomonocyt\u00e1rn\u00ed leukemick\u00e9 bun\u011b\u010dn\u00e9 linie K562 o\u0161et\u0159eny TISF, \u00farove\u0148 apopt\u00f3zy v t\u00e9to bun\u011b\u010dn\u00e9 kultu\u0159e se zv\u00fd\u0161ila v\u00edce ne\u017e dvojn\u00e1sobn\u011b oproti kontrole. Pro srovn\u00e1n\u00ed, TISF nevykazoval \u017e\u00e1dn\u00fd \u00fa\u010dinek na rychlost r\u016fstu bun\u011bk nelymfoidn\u00ed malign\u00ed bun\u011b\u010dn\u00e9 linie, co\u017e dokazuje, \u017ee \u00fa\u010dinek na lymfomov\u00e9 bu\u0148ky nen\u00ed obecn\u00fdm cytotoxick\u00fdm \u00fa\u010dinkem, ani jej nelze p\u0159ipsat syst\u00e9mov\u00e9 imunitn\u00ed reakci vyvolan\u00e9 TISF.<\/p>\n<p>TISF Byl tak\u00e9 testov\u00e1n na \u00fa\u010dinek TISF na ko\u017en\u00ed T-bun\u011b\u010dn\u00fd lymfom (CTCL), za pou\u017eit\u00ed my\u0161\u00edho xenograftov\u00e9ho modelu popsan\u00e9ho T. S. Burgerem a kol., v Experimental Dermatology, sv. 13, 406-12 (2004). Ko\u017en\u00ed T-bun\u011b\u010dn\u00e9 lymfomy (CTCL) jsou skupinou lymfoproliferativn\u00edch poruch postihuj\u00edc\u00edch k\u016f\u017ei. Nejb\u011b\u017en\u011bj\u0161\u00ed formou je mycosis fungoides (MF), p\u0159i kter\u00e9 doch\u00e1z\u00ed k malign\u00edmu r\u016fstu T-bun\u011bk ve form\u011b skvrn a pozd\u011bji n\u00e1dor\u016f na k\u016f\u017ei. Id. Burger, et al., popisuje zp\u016fsob r\u016fstu lidsk\u00fdch MF n\u00e1dor\u016f u nah\u00fdch my\u0161\u00ed s deficitem imunity a ukazuje, \u017ee malign\u00ed bu\u0148ky se \u0161\u00ed\u0159\u00ed do lymfatick\u00fdch uzlin, krevn\u00edho \u0159e\u010di\u0161t\u011b a dal\u0161\u00edch org\u00e1n\u016f. Pomoc\u00ed tohoto modelov\u00e9ho syst\u00e9mu se nyn\u00ed uk\u00e1zalo, \u017ee TISF dramaticky zpomaluje r\u016fst n\u00e1doru CTCL. \u00da\u010dinek se stane z\u0159ejm\u00fdm b\u011bhem dn\u016f po pod\u00e1n\u00ed d\u00e1vky TISF a \u00fa\u010dinek jedn\u00e9 d\u00e1vky pokra\u010duje po dobu alespo\u0148 dvou t\u00fddn\u016f b\u011bhem f\u00e1ze rychl\u00e9ho r\u016fstu modelov\u00e9ho n\u00e1doru, jak je zn\u00e1zorn\u011bno na OBR. 1.<\/p>\n<p>Tato data nazna\u010duj\u00ed, \u017ee malign\u00ed bu\u0148ky a virem infikovan\u00e9 bu\u0148ky lymfoidn\u00edho nebo myeloidn\u00edho p\u016fvodu jsou indukov\u00e1ny TISF k zah\u00e1jen\u00ed apopt\u00f3zy a \u017ee tohoto \u00fa\u010dinku lze dos\u00e1hnout in vivo i in vitro. Tato biologick\u00e1 aktivita TISF m\u016f\u017ee b\u00fdt u\u017eite\u010dn\u011b aplikov\u00e1na na l\u00e9\u010dbu r\u016fzn\u00fdch poruch, kter\u00e9 jsou charakterizov\u00e1ny aberantn\u00edmi T-bu\u0148kami nebo jin\u00fdmi aberantn\u00edmi bu\u0148kami hematopoetick\u00e9ho p\u016fvodu. Mezi takov\u00e9 poruchy pat\u0159\u00ed r\u016fzn\u00e9 lymfomy zahrnuj\u00edc\u00ed T-bu\u0148ky, v\u010detn\u011b T-bun\u011b\u010dn\u00e9ho lymfomu dosp\u011bl\u00fdch, prekurzorov\u00e9ho T-bun\u011b\u010dn\u00e9ho lymfoblastick\u00e9ho lymfomu, extranod\u00e1ln\u00edho p\u0159irozen\u00e9ho zabij\u00e1ck\u00e9ho T-bun\u011b\u010dn\u00e9ho lymfomu, enteropatick\u00e9ho lymfomu typu T-bun\u011bk, hepatosplenick\u00e9ho T-bun\u011b\u010dn\u00e9ho lymfomu, subkut\u00e1nn\u00ed panikulitidy jako T-bun\u011bk lymfom, mycosis fungoides nebo ko\u017en\u00ed T-bun\u011b\u010dn\u00fd lymfom (CTCL), Sezaryho syndrom (leukemick\u00e1 f\u00e1ze CTCL), anaplastick\u00fd velkobun\u011b\u010dn\u00fd lymfom, perifern\u00ed T-bun\u011b\u010dn\u00fd lymfom a angioimunoblastick\u00fd T-bun\u011b\u010dn\u00fd lymfom. Dal\u0161\u00ed poruchy l\u00e9\u010diteln\u00e9 zp\u016fsoby a kompozicemi popsan\u00fdmi v tomto textu zahrnuj\u00ed ur\u010dit\u00e9 leuk\u00e9mie, jako je d\u011btsk\u00e1 leuk\u00e9mie p\u016fvodem z T-bun\u011bk, leuk\u00e9mie dosp\u011bl\u00fdch T-bun\u011bk, lymfocyt\u00e1rn\u00ed leuk\u00e9mie, chronick\u00e1 leuk\u00e9mie T-bun\u011bk, myeloidn\u00ed leuk\u00e9mie a erytroidn\u00ed leuk\u00e9mie. Tyto poruchy tak\u00e9 zahrnuj\u00ed ty virov\u00e9 stavy, kdy jsou infikov\u00e1ny lymfocyty a konkr\u00e9tn\u011b je zahrnuta infekce HIV. TISF m\u016f\u017ee prosp\u00edvat subjekt\u016fm maj\u00edc\u00edm HIV tak\u00e9 jin\u00fdmi zp\u016fsoby, kv\u016fli sv\u00fdm imunostimula\u010dn\u00edm \u00fa\u010dink\u016fm a podpo\u0159e hematopo\u00e9zy, ale p\u0159edkl\u00e1dan\u00fd vyn\u00e1lez poskytuje zp\u016fsob indukce apopt\u00f3zy aberantn\u00edch T-bun\u011bk a t\u00edm sn\u00ed\u017een\u00ed virov\u00e9 z\u00e1t\u011b\u017ee u pacient\u016f s HIV.<\/p>\n<p>Lymfomov\u00e9 bu\u0148ky byly inkubov\u00e1ny po dobu 48 hodin v p\u0159\u00edtomnosti TISF v n\u011bkolika r\u016fzn\u00fdch koncentrac\u00edch. Bu\u0148ky byly pot\u00e9 o\u0161et\u0159eny 3H-thymidinem pro m\u011b\u0159en\u00ed bun\u011b\u010dn\u00e9 proliferace. P\u0159i ka\u017ed\u00e9 koncentraci TISF inhiboval bun\u011b\u010dn\u00fd r\u016fst. Jako kontrola pro stanoven\u00ed, zda \u00fa\u010dinek byl obecnou cytotoxicitou, byla nelymfoidn\u00ed malign\u00ed bun\u011b\u010dn\u00e1 linie tak\u00e9 o\u0161et\u0159ena TISF a TISF nem\u011bl v tomto p\u0159\u00edpad\u011b \u017e\u00e1dn\u00fd vliv na rychlost r\u016fstu.<\/p>\n<p>Lymfocyty infikovan\u00e9 virem HIV byly inkubov\u00e1ny s TISF v r\u016fzn\u00fdch d\u00e1vk\u00e1ch. Bun\u011b\u010dn\u00e1 smrt nastala p\u0159i ka\u017ed\u00e9 testovan\u00e9 koncentraci a rozsah byl z\u00e1visl\u00fd na d\u00e1vce. Nav\u00edc koncentrace TISF korelovala se sn\u00ed\u017eenou produkc\u00ed viru.<\/p>\n<p>Lidsk\u00e1 myelomonocyt\u00e1rn\u00ed leukemick\u00e1 bun\u011b\u010dn\u00e1 linie K562 byla inkubov\u00e1na s TISF. Rychlost apopt\u00f3zy se zv\u00fd\u0161ila v\u00edce ne\u017e dvojn\u00e1sobn\u011b oproti rychlosti v kontroln\u00ed kultu\u0159e.<\/p>\n<p>Modelov\u00e9 n\u00e1dory ko\u017en\u00edho T-bun\u011b\u010dn\u00e9ho lymfomu (CTCL) byly zalo\u017eeny u my\u0161\u00ed metodou popsanou v T. S. Burger, et al., Stanoven\u00ed my\u0161\u00edho xenograftov\u00e9ho modelu pro mycosis fungoides, Experimental Dermatology, 13, 406-412 (2004). P\u0159ibli\u017en\u011b 14 dn\u00ed po implantaci n\u00e1dorov\u00fdch bun\u011bk byly my\u0161i o\u0161et\u0159eny TISF. Objem n\u00e1doru v mm3 byl vyhodnocen podle Burgera, et al., jako Velikost = d\u00e9lka x (\u0161\u00ed\u0159ka) 2 x 0,5. P\u0159ibli\u017en\u011b v dob\u011b l\u00e9\u010dby se rychlost r\u016fstu n\u00e1doru prudce zv\u00fd\u0161ila u nel\u00e9\u010den\u00fdch my\u0161\u00ed, zat\u00edmco jedna d\u00e1vka TISF v\u00fdznamn\u011b potla\u010dila rychlost r\u016fstu n\u00e1doru u l\u00e9\u010den\u00fdch zv\u00ed\u0159at. V\u00fdsledky jsou shrnuty na OBR. 1, 4 a 5. Obr. 1 ukazuje, \u017ee objem n\u00e1doru byl v\u00edce ne\u017e dvakr\u00e1t v\u011bt\u0161\u00ed u nel\u00e9\u010den\u00fdch my\u0161\u00ed ne\u017e u l\u00e9\u010den\u00fdch my\u0161\u00ed t\u0159i dny po l\u00e9\u010db\u011b. OBR. 4 ukazuje, \u017ee siln\u00fd \u00fa\u010dinek z jedn\u00e9 d\u00e1vky je udr\u017eov\u00e1n alespo\u0148 19 dn\u00ed po jedin\u00e9m o\u0161et\u0159en\u00ed a \u017ee \u00fa\u010dinek je mnohem siln\u011bj\u0161\u00ed, kdy\u017e se pou\u017eije purifikovan\u00e1 kompozice TISF. OBR. 5 ilustruje, \u017ee \u00fa\u010dinek TISF je z\u00e1visl\u00fd na d\u00e1vce.<\/p>\n<p>\u0160est t\u00fddn\u016f star\u00e9 nah\u00e9 my\u0161i NMRI byly z\u00edsk\u00e1ny od Harlan Winkelmann, Borchen, N\u011bmecko byly chov\u00e1ny v individu\u00e1ln\u00edch ventilovan\u00fdch klec\u00edch, potrava a voda ad libitum. CTCL n\u00e1dorov\u00e1 tk\u00e1\u0148 byla implantov\u00e1na v anestezii do boku zv\u00ed\u0159at 24. listopadu 2004 a velikost n\u00e1doru byla monitorov\u00e1na dvakr\u00e1t t\u00fddn\u011b za pou\u017eit\u00ed metod popsan\u00fdch v Experimental Dermatology, 13, 406-412 (2004). Skupiny po 10 zv\u00ed\u0159atech byly pou\u017eity pro l\u00e9\u010debnou skupinu a kontroln\u00ed skupinu.<\/p>\n<p>Zv\u00ed\u0159ata v l\u00e9\u010debn\u00e9 skupin\u011b byla o\u0161et\u0159ena 100 \u00a0\u03bcl injekcemi rekonstituovan\u00e9ho roztoku TISF; zv\u00ed\u0159at\u016fm kontroln\u00ed skupiny bylo injikov\u00e1no 100 \u00a0\u03bcl z\u0159ed\u011bn\u00e9ho fyziologick\u00e9ho roztoku. L\u00e9\u010dba byla pod\u00e1v\u00e1na denn\u011b n\u00e1sledovn\u011b: 13.-17. prosince 2004; 20.-24. prosince 2004; 27.-31. prosince 2004; a 3.-5. ledna 2005. Zv\u00ed\u0159ata byla utracena 6. ledna 2005.<\/p>\n<p>Kdy\u017e l\u00e9\u010dba za\u010dala, objem n\u00e1doru byl p\u0159ibli\u017en\u011b 80 mm3. OBR. 2 ukazuje rychlost r\u016fstu n\u00e1doru v kontroln\u00ed skupin\u011b (reprezentovan\u00e9 \u010dtvercov\u00fdmi datov\u00fdmi body) a l\u00e9\u010den\u00e9 skupin\u011b (reprezentovan\u00e9 datov\u00fdmi body ve tvaru koso\u010dtverce) a ukazuje, \u017ee l\u00e9\u010dba podstatn\u011b zpomalila r\u016fst n\u00e1doru. Kdy\u017e byla zv\u00ed\u0159ata usmrcena, objem n\u00e1doru byl t\u00e9m\u011b\u0159 t\u0159ikr\u00e1t v\u011bt\u0161\u00ed u nel\u00e9\u010den\u00fdch (kontroln\u00edch) zv\u00ed\u0159at ve srovn\u00e1n\u00ed s l\u00e9\u010den\u00fdmi zv\u00ed\u0159aty. OBR. 3 ukazuje t\u011blesn\u00e9 hmotnosti zv\u00ed\u0159at a ukazuje, \u017ee l\u00e9\u010dba TISF nem\u011bla \u017e\u00e1dn\u00fd v\u00fdznamn\u00fd \u00fa\u010dinek na celkovou rychlost r\u016fstu l\u00e9\u010den\u00fdch zv\u00ed\u0159at.<\/p>\n<p>Tk\u00e1\u0148 z n\u00e1dor\u016f byla obarvena hematoxylinem a eosinem pro histologick\u00e9 vy\u0161et\u0159en\u00ed. N\u00e1dorov\u00e1 tk\u00e1\u0148 z l\u00e9\u010den\u00fdch zv\u00ed\u0159at vykazovala m\u00edrn\u00e9 zv\u00fd\u0161en\u00ed koagula\u010dn\u00ed nekr\u00f3zy a m\u00edrn\u00e9 zv\u00fd\u0161en\u00ed angiogeneze ve srovn\u00e1n\u00ed s kontrolami. OBR. 4 ukazuje v\u00fdsledky histologick\u00e9ho vy\u0161et\u0159en\u00ed ka\u017ed\u00e9ho zv\u00ed\u0159ete a Obr. 5 ukazuje reprezentativn\u00ed sn\u00edmky n\u00e1dorov\u00e9 tk\u00e1n\u011b z l\u00e9\u010den\u00fdch a nel\u00e9\u010den\u00fdch zv\u00ed\u0159at.<\/p>\n\t\t\n<style>\n#text-2966089267 {\n  color: rgb(0,0,0);\n}\n#text-2966089267 > * {\n  color: rgb(0,0,0);\n}\n<\/style>\n\t<\/div>\n\t\n<div class=\"row\"  id=\"row-2113046137\">\n\n\n\t<div id=\"col-1342622819\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner text-center\" style=\"background-color:rgb(213, 218, 232);\" >\n\t\t\t\n\t\t\t\n\n\t<div id=\"gap-1407423729\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1407423729 {\n  padding-top: 30px;\n}\n<\/style>\n\t<\/div>\n\t\n\n<div class=\"row\"  id=\"row-645184947\">\n\n\n\t<div id=\"col-147846118\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner text-center\"  >\n\t\t\t\n\t\t\t\n\n\t<div id=\"text-4193785623\" class=\"text\">\n\t\t\n\n<h5>galery - slider\u00a0<\/h5>\n\t\t\n<style>\n#text-4193785623 {\n  color: rgb(0,0,0);\n}\n#text-4193785623 > * {\n  color: rgb(0,0,0);\n}\n<\/style>\n\t<\/div>\n\t\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n<\/div>\n<div class=\"row\"  id=\"row-2001183829\">\n\n\n\t<div id=\"col-1951281778\" class=\"col medium-8 small-12 large-8\"  >\n\t\t\t\t<div class=\"col-inner text-center\"  >\n\t\t\t\n\t\t\t\n\n<div class=\"slider-wrapper relative\" id=\"slider-498464014\" >\n    <div class=\"slider slider-nav-circle slider-nav-large slider-nav-light slider-style-normal\"\n        data-flickity-options='{            \"cellAlign\": \"center\",            \"imagesLoaded\": true,            \"lazyLoad\": 1,            \"freeScroll\": false,            \"wrapAround\": true,            \"autoPlay\": 6000,            \"pauseAutoPlayOnHover\" : true,            \"prevNextButtons\": true,            \"contain\" : true,            \"adaptiveHeight\" : true,            \"dragThreshold\" : 10,            \"percentPosition\": true,            \"pageDots\": true,            \"rightToLeft\": false,            \"draggable\": true,            \"selectedAttraction\": 0.1,            \"parallax\" : 0,            \"friction\": 0.6        }'\n        >\n        \n\n\t<div class=\"img has-hover x md-x lg-x y md-y lg-y\" id=\"image_559521036\">\n\t\t\t\t\t\t\t\t<div class=\"img-inner dark\" >\n\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"824\" height=\"1024\" src=\"https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/US07776818-20100817-D00001-824x1024.png\" class=\"attachment-large size-large\" alt=\"\" srcset=\"https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/US07776818-20100817-D00001-824x1024.png 824w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/US07776818-20100817-D00001-510x634.png 510w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/US07776818-20100817-D00001-241x300.png 241w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/US07776818-20100817-D00001-768x955.png 768w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/US07776818-20100817-D00001-1235x1536.png 1235w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/US07776818-20100817-D00001-1647x2048.png 1647w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/US07776818-20100817-D00001-10x12.png 10w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/US07776818-20100817-D00001-500x622.png 500w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/US07776818-20100817-D00001-800x995.png 800w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/US07776818-20100817-D00001-1280x1591.png 1280w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/US07776818-20100817-D00001-1920x2387.png 1920w\" sizes=\"auto, (max-width: 824px) 100vw, 824px\" \/>\t\t\t\t\t\t\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\n<style>\n#image_559521036 {\n  width: 100%;\n}\n<\/style>\n\t<\/div>\n\t\n\n\t<div class=\"img has-hover x md-x lg-x y md-y lg-y\" id=\"image_55768053\">\n\t\t\t\t\t\t\t\t<div class=\"img-inner dark\" >\n\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"1020\" height=\"803\" src=\"https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/US07776818-20100817-D00002-1024x806.png\" class=\"attachment-large size-large\" alt=\"\" srcset=\"https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/US07776818-20100817-D00002-1024x806.png 1024w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/US07776818-20100817-D00002-510x402.png 510w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/US07776818-20100817-D00002-300x236.png 300w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/US07776818-20100817-D00002-768x605.png 768w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/US07776818-20100817-D00002-15x12.png 15w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/US07776818-20100817-D00002-500x394.png 500w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/US07776818-20100817-D00002-800x630.png 800w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/US07776818-20100817-D00002.png 1158w\" sizes=\"auto, (max-width: 1020px) 100vw, 1020px\" \/>\t\t\t\t\t\t\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\n<style>\n#image_55768053 {\n  width: 100%;\n}\n<\/style>\n\t<\/div>\n\t\n\n\t<div class=\"img has-hover x md-x lg-x y md-y lg-y\" id=\"image_717227794\">\n\t\t\t\t\t\t\t\t<div class=\"img-inner dark\" >\n\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"1020\" height=\"823\" src=\"https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/US07776818-20100817-D00003-1024x826.png\" class=\"attachment-large size-large\" alt=\"\" srcset=\"https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/US07776818-20100817-D00003-1024x826.png 1024w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/US07776818-20100817-D00003-510x411.png 510w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/US07776818-20100817-D00003-300x242.png 300w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/US07776818-20100817-D00003-768x619.png 768w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/US07776818-20100817-D00003-1536x1238.png 1536w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/US07776818-20100817-D00003-15x12.png 15w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/US07776818-20100817-D00003-500x403.png 500w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/US07776818-20100817-D00003-800x645.png 800w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/US07776818-20100817-D00003-1280x1032.png 1280w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/US07776818-20100817-D00003.png 1589w\" sizes=\"auto, (max-width: 1020px) 100vw, 1020px\" \/>\t\t\t\t\t\t\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\n<style>\n#image_717227794 {\n  width: 100%;\n}\n<\/style>\n\t<\/div>\n\t\n\n\t<div class=\"img has-hover x md-x lg-x y md-y lg-y\" id=\"image_1465422380\">\n\t\t\t\t\t\t\t\t<div class=\"img-inner dark\" >\n\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"1020\" height=\"757\" src=\"https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/US07776818-20100817-D00004-1024x760.png\" class=\"attachment-large size-large\" alt=\"\" srcset=\"https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/US07776818-20100817-D00004-1024x760.png 1024w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/US07776818-20100817-D00004-510x378.png 510w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/US07776818-20100817-D00004-300x223.png 300w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/US07776818-20100817-D00004-768x570.png 768w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/US07776818-20100817-D00004-1536x1139.png 1536w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/US07776818-20100817-D00004-2048x1519.png 2048w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/US07776818-20100817-D00004-16x12.png 16w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/US07776818-20100817-D00004-500x371.png 500w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/US07776818-20100817-D00004-800x593.png 800w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/US07776818-20100817-D00004-1280x950.png 1280w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/US07776818-20100817-D00004-1920x1424.png 1920w\" sizes=\"auto, (max-width: 1020px) 100vw, 1020px\" \/>\t\t\t\t\t\t\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\n<style>\n#image_1465422380 {\n  width: 100%;\n}\n<\/style>\n\t<\/div>\n\t\n\n\t<div class=\"img has-hover x md-x lg-x y md-y lg-y\" id=\"image_1205400890\">\n\t\t\t\t\t\t\t\t<div class=\"img-inner dark\" >\n\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"843\" height=\"1024\" src=\"https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/US07776818-20100817-D00005-843x1024.png\" class=\"attachment-large size-large\" alt=\"\" srcset=\"https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/US07776818-20100817-D00005-843x1024.png 843w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/US07776818-20100817-D00005-510x619.png 510w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/US07776818-20100817-D00005-247x300.png 247w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/US07776818-20100817-D00005-768x932.png 768w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/US07776818-20100817-D00005-1265x1536.png 1265w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/US07776818-20100817-D00005-1687x2048.png 1687w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/US07776818-20100817-D00005-10x12.png 10w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/US07776818-20100817-D00005-500x607.png 500w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/US07776818-20100817-D00005-800x971.png 800w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/US07776818-20100817-D00005-1280x1554.png 1280w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/US07776818-20100817-D00005.png 1729w\" sizes=\"auto, (max-width: 843px) 100vw, 843px\" \/>\t\t\t\t\t\t\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\n<style>\n#image_1205400890 {\n  width: 100%;\n}\n<\/style>\n\t<\/div>\n\t\n\n\t<div class=\"img has-hover x md-x lg-x y md-y lg-y\" id=\"image_2037710435\">\n\t\t\t\t\t\t\t\t<div class=\"img-inner dark\" >\n\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"982\" height=\"1024\" src=\"https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/US07776818-20100817-D00006-982x1024.png\" class=\"attachment-large size-large\" alt=\"\" srcset=\"https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/US07776818-20100817-D00006-982x1024.png 982w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/US07776818-20100817-D00006-510x532.png 510w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/US07776818-20100817-D00006-288x300.png 288w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/US07776818-20100817-D00006-768x801.png 768w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/US07776818-20100817-D00006-1473x1536.png 1473w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/US07776818-20100817-D00006-12x12.png 12w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/US07776818-20100817-D00006-500x521.png 500w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/US07776818-20100817-D00006-800x834.png 800w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/US07776818-20100817-D00006-1280x1334.png 1280w, https:\/\/proboostnow.eu\/wp-content\/uploads\/2023\/03\/US07776818-20100817-D00006.png 1720w\" sizes=\"auto, (max-width: 982px) 100vw, 982px\" \/>\t\t\t\t\t\t\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\n<style>\n#image_2037710435 {\n  width: 100%;\n}\n<\/style>\n\t<\/div>\n\t\n\n\n     <\/div>\n\n     <div class=\"loading-spin dark large centered\"><\/div>\n\n\t<\/div>\n\n\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n<\/div>\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n\n<style>\n#row-2113046137 > .col > .col-inner {\n  background-color: rgb(213, 218, 232);\n}\n<\/style>\n<\/div>\n<div class=\"row\"  id=\"row-1181340173\">\n\n\n\t<div id=\"col-1304382967\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n\n<p>zdroj:<\/p>\n<p>informace sd\u011blen\u00e9 Dr. Terry Beardsleyem, Ph.D.\u00a0<\/p>\n<p>https:\/\/patents.google.com\/patent\/US7776818B2\/en?oq=us7776818<\/p>\n<p>https:\/\/patents.google.com\/patent\/US20070190025A1\/en<\/p>\n<p>https:\/\/patents.google.com\/patent\/US5616554A\/en<\/p>\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n<\/div>\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n<\/div>\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n\n<\/div>","protected":false},"excerpt":{"rendered":"","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-1838","page","type-page","status-publish","hentry"],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/proboostnow.eu\/en_us\/wp-json\/wp\/v2\/pages\/1838","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/proboostnow.eu\/en_us\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/proboostnow.eu\/en_us\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/proboostnow.eu\/en_us\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/proboostnow.eu\/en_us\/wp-json\/wp\/v2\/comments?post=1838"}],"version-history":[{"count":0,"href":"https:\/\/proboostnow.eu\/en_us\/wp-json\/wp\/v2\/pages\/1838\/revisions"}],"wp:attachment":[{"href":"https:\/\/proboostnow.eu\/en_us\/wp-json\/wp\/v2\/media?parent=1838"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}